Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.

Sugen Incorporated

The University of Texas System

Other

Hadasit Medical Research Services and Development Ltd.

Rhone-poulenc Rorer Pharmaceuticals Inc.

Targimmune Therapeutics Ag

Yissum Research Development

Novotyr Therapeutics Ltd.

Develogen Israel Ltd.

Notox, Ltd.

Alexander Levitzki

Levitzki, Alexander

Moshe Talpaz

Nicholas Donato

Aviv Gazit

Peng Cho Tang

Chaim Gilon

Hadas Reuveni

Harald App

Alexei Shir

Gerald M McMahon

Waldemar Priebe

Izabela Fokt

Slawomir Szymanski

Nicholas J Donato

Eyal Yosef Mishani

Alfred P Spada

Paul E Persons

Gershon Golomb

Klaus Peter Hirth

Laura Kay Shawver

Elaina Mann

Iris Ben-David

Yael Langut

Jianming Tsai

Hui Chen

Shmuel Banai

Yulia Rozen

Shmuel A Ben-Sasson

Michael Chorev

S David Gertz

Frank D Boehmer

Johannes Waltenberger

Giuseppina Ortu

Revital Sasson

Ehud Cohen

Andre C B Lucassen

Nurit Livnah

Maya Zigler

David Gertz

Galith Abourbeh

Nufar Edinger

Idit Sagiv

Samar Dissoki

Lilach Steiner

Thomas Bonasera

Avi Weissberg

Eric Kitas

Esteban Pombo-Villar

Abraham Novogrodsky

Gluseppina Ortu

Described herein are recombinant chimeric proteins comprising a double stranded RNA (dsRNA) binding domain and a cancer-cell targeting domain for targeting of dsRNA to cancer cells. Methods of use of the described chimeric proteins are also provided herein.

Chimeric proteins for targeting dsRNA

The present invention relates to a polyplex for use in the treatment of castration resistant prostate cancer (CRPC) comprising a double stranded RNA (dsRNA) and a polymeric conjugate, wherein said polymeric conjugate consists of a linear polyethyleneimine (LPEl), one or more polyethylene glycol (PEG) moieties, one or more linkers and one or more targeting moieties, wherein said LPEl is covalently bound to one or more PEG moieties and each of said one or more PEG moieties is conjugated via one of the one or more linkers to one of the one or more targeting moieties, wherein each of said one or more targeting moieties is capable of binding to a cancer antigen, and wherein said cancer antigen is prostate surface membrane antigen (PSMA). Further, the invention relates to a pharmaceutical composition for use in the treatment of CRPC.

Castration resistant prostate cancer

The present invention provides compounds acting as Insulin/IGF signaling modulators useful in the treatment of neurodegenerative diseases and disorders. The invention provides pharmaceutical compositions including such compounds, and methods of using these compounds and compositions for the treatment of neurodegenerative diseases, in particular neurodegenerative diseases caused by proteotoxicity such as Alzheimer's disease.

IGF-1R signaling pathway inhibitors useful in the treatment of neurodegenerative diseases

The present invention concerns compounds and their use to treat cell proliferative diseases such as cancer. Compounds of the present invention display significant potency as kinase inhibitors, cause the downregulation of c-myc, and inhibit the growth and survival of cancerous cell lines.

Compounds for treatment of cell proliferative diseases

The present invention provides compounds of formula (1) acting as protein kinase (PK) and receptor kinase (RK) signaling modulators. The invention further provides methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as anti-cancer agents for preventions and treatments of PK- and RK-related disorders, in particular cancer. (I) wherein A is H or CN; Z is S, SO or S0; X, X, X, X, X, Yand Yare each independently selected from H, halogen, alkyl, haloalkyl and OR; and Yand Yare each OR, wherein each Ris independently H, C-Calkyl, acyl, &#x2014;(CHCH0)wherein n is an integer of 1 to 20, or a functional group that gives rise to hydroxyl upon hydrolysis. 

2-(2-phenylethenyl) 1,3-benzodiazepine derivatives useful for the treatment of cancer

An epidermal growth factor receptor (EGFR)-homing vector comprising a double-stranded RNA (dsRNA) molecule with an EGFR-binding peptide or polypeptide, is disclosed for use in combination with immune cells for treatment of cancer overexpressing EGFR.

EGFR-homing double-stranded RNA vector for systemic cancer treatment

Quinazoline derivatives are provided that specifically inhibit proliferation of T cells without affecting the level of IL-2 secreted from said T cells. These compounds as well as pharmaceutical composition comprising them are useful for the treatment of indications mediated by T cell proliferation.

Quinazoline-based T cell proliferation inhibitors

The present invention provides new tyrphostin derivatives acting as protein kinase (PK) and receptor kinase (RK) signaling modulators. The invention further provides methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PK and RK related disorders such as metabolic, inflammatory, fibrotic, and cell proliferative disorders, in particular cancer.

Modulators of protein kinase signaling

Novel epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors, pharmaceutical compositions including same and their use in the treatment of EGFR-TK related diseases or disorders are disclosed. Novel radiolabeled EGFR-TK inhibitors as their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are further disclosed. The disclosed EGFR-TK inhibitors comprise a polyalkylene glycol moiety and/or a hydroxy-containing moiety and are characterized by improved solubility, biostability and bioavailability. Processes of preparing the disclosed EGFR-TK inhibitors and of radiolabeling same, via, for example, one-step radiosyntheses, are also disclosed.

Polyalkylene glycol derivatives of inhibitors of epidermal growth factor receptor tyrosine kinase

A method of killing a specific target cell/tissue is disclosed. The method comprises exposing the specific target cell/tissue to a composition-of-matter which comprises a double stranded RNA molecule associated with a targeting moiety selected capable of targeting to the specific target cell/tissue, thereby killing the specific target cell/tissue.

Targeted double stranded RNA mediated cell killing

The present invention provides new tyrphostin derivatives acting as substrate competitive protein tyrosine kinase (PTK) inhibitors and receptor tyrosine kinase (RTK) inhibitors, methods of their preparation, pharmaceutical compositions including such compounds, and methods of using these compounds and compositions, especially as chemotherapeutic agents for preventions and treatments of PTK and RTK related disorders such as metabolic, fibrotic, and cell proliferative disorders, in particular psoriasis and cancer.

Protein kinase modulators and therapeutic uses thereof

Growing community of inventors

Jerusalem, Israel

Alexander Levitzki